Abivax SA Aktie

104,40 EUR +2,80 EUR +2,76 %

19:04:00

STU

94,49 CHF +4,69 CHF +5,22 %

17:29:50

BRX

Abivax SA jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.7,99 Mrd. EUR

Div. Rendite0,00%

WKNA14UQC

ISINFR0012333284

SymbolAAVXF

Abivax SA Aktien News

Sortieren:Datum Meistgelesen

15.07.24EQS GroupEQS-News: Abivax Provides Operational and Key Program Update

05.04.24EQS GroupEQS-News: Abivax publishes financial reports with the French and U.S. securities regulatory agencies

02.04.24EQS GroupEQS-News: Abivax reports 2023 financial results and operational update

07.02.24EQS GroupEQS-News: Abivax appoints Ana Sharma as Vice President, Global Head of Quality

02.02.24EQS GroupEQS-News: Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease

22.01.24EQS GroupEQS-News: Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months

04.01.24EQS GroupEQS-News: Abivax 2024 Financial Communication Calendar

21.11.23EQS GroupEQS-News: Abivax announces the resumption of its liquidity contract

14.11.23EQS GroupEQS-News: Abivax to participate in the Piper Sandler 35th Annual Healthcare Conference

24.10.23EQS GroupEQS-News: Abivax announces Closing of its Initial Public Offering on the Nasdaq Global Market

20.10.23EQS GroupEQS-News: Abivax announces trading resumption of its ordinary shares on Euronext Paris

20.10.23EQS GroupEQS-News: Abivax announces the pricing of its Initial Public Offering on the Nasdaq Global Market

20.10.23EQS GroupEQS-News: Abivax announces temporary trading halt of its ordinary shares on Euronext Paris

19.10.23EQS GroupEQS-News: Abivax announces the filing of an amended registration statement, including an estimated initial public offering price range

16.10.23EQS GroupEQS-News: Abivax announces the start of the roadshow for its proposed global offering and proposed Nasdaq listing

02.10.23EQS GroupEQS-News: Abivax highlights obefazimod ulcerative colitis program with new data to be presented at the UEG Week 2023

29.09.23EQS GroupEQS-News: Abivax files registration statement for proposed initial public offering in the United States

29.09.23EQS GroupEQS-News: Abivax announces the release of its 2023 half-year financial report

21.09.23EQS GroupEQS-News: Abivax presents first-half 2023 financial results

07.09.23EQS GroupEQS-News: Abivax provides business and operational update

23.08.23EQS GroupEQS-News: Abivax appoints Patrick Malloy as Senior Vice President Investor Relations

21.08.23EQS GroupEQS-News: Abivax secures up to EUR 150M from two structured debt financing transactions

10.08.23EQS GroupEQS-News: Abivax announces plans to conduct registered public offering in the United States

11.07.23EQS GroupEQS-News: Abivax announces the appointment of June Lee, M.D. and Troy Ignelzi as Members of the Board of Directors

15.06.23EQS GroupEQS-News: Abivax receives Capital Market Transaction of the Year Award at the European Mediscience Awards 2023

08.06.23EQS GroupEQS-News: Abivax stock included in MSCI Indexes

08.06.23EQS GroupEQS-News: Abivax releases the results of its June 5, 2023 ordinary and extraordinary general meeting

08.06.23EQS GroupEQS-News: Abivax appoints Ida Hatoum as Chief People Officer

15.05.23EQS GroupEQS-News: Abivax announces its ordinary and extraordinary general meeting of June 5, 2023, and the availability of the preparatory documents

04.05.23EQS GroupEQS-News: Abivax publishes Universal Registration Document 2023 Document dEnregistrement Universel

02.05.23EQS GroupEQS-News: Abivax: Publication of an expert article in JCC on obefazimod as promising therapeutic management option for UC patients

19.04.23EQS GroupEQS-News: Abivax reports 2022 financial results and operations update

18.04.23EQS GroupEQS-News: Abivax appoints Michael Ferguson as Chief Commerical Officer

17.04.23EQS GroupEQS-News: Abivax reports two-year efficacy and safety data of obefazimod phase 2b maintenance trial in ulcerative colitis

05.04.23EQS GroupEQS-News: Abivax appoints Marc de Garidel as Chief Executive Officer and Interim Board Chair

16.03.23EQS GroupEQS-News: Abivax adjusts its 2023 Financial Communication Calendar

13.03.23EQS GroupEQS-News: Abivax does not hold any cash or otherwise have any deposits at SVB or at any other U.S. financial institution

23.02.23EQS GroupEQS-News: Abivax publishes a prospectus in the context of its capital increase

22.02.23EQS GroupEQS-News: Abivax announces successful oversubscribed EUR 130M cross-over financing at market price with top-tier US and European biotech investors

17.02.23EQS GroupEQS-News: Abivax appoints Dr. Sheldon Sloan, M.D., as Chief Medical Officer

Abivax SA News

Abivax SA News: auf dieser Seite finden Sie alle Abivax SA News und Nachrichten zur Abivax SA Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Abivax SA News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Abivax SA News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.